precemtabart tocentecan (M9140) / EMD Serono 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
precemtabart tocentecan (M9140) / EMD Serono
PROCEADE PanTumor, NCT06710132: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors

Not yet recruiting
1/2
250
Europe, US
M9140
EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
01/29
01/29
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26

Download Options